throbber
United States Patent [19]
`Cottens et al.
`
`II 11111111111111
`
`US005665772A
`[11] Patent Number:
`[45] Date of Patent:
`
`5,665,772
`Sep.9, 1997
`
`[54] 0-ALKYLATED RAPAMYCIN DERIVATIVES
`AND THEIR USE, PARTICULARLY AS
`~OSUPPRESSANTS
`
`Int. Cl.6
`•.••••••••..•.••••••••• A61K 31/395; C07D 498/16
`[51]
`[52] U.S. Cl .............................................. 514/514; 540/456
`[58] Field of Search .............................. 540/456; 514/514
`
`[75]
`
`Inventors: Sylvain Cottens, Witterswil; Richard
`Sedrani. Basel, both of Switzerland
`
`[56]
`
`References Cited
`U.S. PA1ENT DOCUMENTS
`
`[73] Assignee: Sandoz Ltd., Basel, Switzerland
`
`[21] Appl. No.:
`
`416,673
`
`[22] PCT Filed:
`
`Sep. 24, 1993
`
`[86] PCTNo.:
`
`PCTIEP93/02604
`
`§ 371 Date:
`
`Apr. 7, 1995
`
`§ 102(e) Date: Apr. 7,1995
`
`[87] PCT Pub. No.: W094/09010
`
`PCT Pub. Date: Apr. 28, 1994
`
`[30]
`
`Foreign Application Priority Data
`
`6/1992 Failli et al .....••..•.•..•.........•..... 540/542
`5,120,842
`9/1992 Caufield et al ........................... 514/63
`5,151,413
`5,258,389 1111993 Goulet et al ............................ 514/291
`Primary Examiner-Robert T. Bond
`Attorney, Agent, or Finn-Robert S. Honor; Melvyn M.
`Kassenoff; Thomas 0. McGovern
`[57]
`ABSTRACT
`
`Novel derivatives of rapamycin, particularly
`9-deoxorapamycins. 26-dihydro-rapamycins. and 40-0-
`substituted and 28.40-0,0-di-substituted rapamycins, are
`found to have pharmaceutical utility, particularly as an
`immunosuppressants.
`
`Oct. 9, 1992
`
`[GB] United Kingdom ................... 9221220
`
`10 Claims, No Drawings
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 001
`
`

`
`1
`0-ALKYLATED RAPAMYCIN DERIVATIVES
`AND THEIR USE, PARTICULARLY AS
`~OSUPPRESSANTS
`
`5,665,772
`
`2
`
`(I)
`
`50
`
`55
`
`24
`
`:
`
`This application is a 371 of Pcr/EP93/02604, filed Sep. 5
`24, 1993.
`This invention comprises novel alkylated derivatives of
`rapamycin having pharmaceutical utility, especially as
`immunosuppressants.
`Rapamycin is a known macrolide antibiotic produced by 10
`Streptomyces hygroscopicus, having the structure depicted
`in Formula A:
`
`X is (H,H) or 0;
`Y is (H,OH) or 0;
`R1 and R2 are independently selected from H, alkyl,
`thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl,
`hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl,
`alkoxyalkyl, acyloxyalkyl, aminoalkyl,
`alkylaminoalkyl, alkoxycarbonylaminoalkyl,
`acylaminoalkyL arylsulfonamidoalkyl, allyl,
`dihydroxyalkylallyl, dioxolanylallyl, carbalkoxyalkyl,
`and (R3
`) 3Si where each R3 is independently selected
`from H, methyl, ethyl, isopropyl, t-butyl, and phenyl;
`wherein "alk-" or "alkyl" refers to c1-6 alkyl, branched
`or linear preferably c1-3 alkyl, in which the carbon
`chain may be optionally interrupted by an ether
`(-0-) linkage; and
`R4 is methyl, or R4 and R1 together form C2_5 alkylene;
`provided that R1 and R2 are not both H; and provided that
`where R 1 is (R3hSi or carbalkoxyalkyl, X andY are not both
`0.
`Preferred Novel Compounds include the following:
`1. 40-0-Benzyl-rapamycin
`2. 40-0-( 4'-Hydroxymethyl)benzyl-rapamycin
`3. 40-0-[ 4' -( 1,2-Dihydroxyethyl) ]benzyl-rapamycin
`4. 40-0-Allyl-rapamycin
`5. 40-0-[3'-(2,2-Dimethyl-13-dioxolan-4(S)-yl)-prop-2'(cid:173)
`en-1'-yl]-rapamycin
`6. (2'E,4'S)-40-0-( 4' ,5' -Dihydroxypent-2' -en-1 '-yl)-
`rapamycin
`7. 40-0-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin
`8. 40-0-(2-Hydroxy)ethyl-rapamycin
`9. 40-0-(3-Hydroxy )propyl-rapamycin
`See, e.g., McAlpine, J. B., et al., J. Antibiotics (1991) 44:
`10. 40-0-(6-Hydroxy)hexyl-rapamycin
`688; Schreiber, S. L., et al., J. Am. Chern. Soc. (1991) 113:
`11. 40-0-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin
`12. 40-0-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-
`7433; U.S. Pat. No. 3,929,992. Rapamycin is an extremely
`rapamycin
`potent immunosuppressant and has also been shown to have 35
`13. 40-0-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin
`antitumor and antifungal activity. Its utility as a
`pharmaceutical, however, is restricted by its very low and
`14. 40-0-(2-Acetoxy)ethyl-rapamycin
`variable bioavailability as well as its high toxicity.
`15. 40-0-(2-Nicotinoyloxy)ethyl-rapamycin
`Moreover, rapamycin is highly insoluble, making it difficult
`16. 40-0-[2-(N-Morpholino)acetoxy]ethyl-rapamycin
`40 17. 40-0-(2-N-Imidazolylacetoxy)ethyl-rapamycin
`to formulate stable galenic compositions.
`18. 40-0-[2-(N-Methyl-N'-piperazinyl)acetoxy]ethyl-
`It has now surprisingly been discovered that certain novel
`derivatives of rapamycin (the Novel Compounds) have an
`rapamycin
`19. 39-0-Desmethyl-39,40-0,0-ethylene-rapamycin
`improved pharmacologic profile over rapamycin, exhibit
`20. (26R)-26-Dihydro-40-0-(2-hydroxy)ethyl-rapamycin
`greater stability and bioavailability, and allow for greater
`ease in producing galenic formulations. The Novel Com- 45 21. 28-0-Methyl-rapamycin
`pounds are alkylated derivatives of rapamycin having the
`22. 40-0-(2-Aminoethyl)-rapamycin
`structure of Formula 1:
`23. 40-0-(2-Acetaminoethyl)-rapamycin
`24. 40-0-(2-Nicotinamidoethyl)-rapamycin
`25. 40-0-(2-(N-Methyl-imidazo-2'-ylcarbethoxamido)
`ethyl)-rapamycin
`26. 40-0-(2-Ethoxycarbonylaminoethyl)-rapamycin
`27. 40-0-(2-Tolylsulfonamidoethyl)-rapamycin
`28. 40-0-[2-( 4' ,5'-Dicarboethoxy-1' ,2' ,3'-triazol-1 '-yl)(cid:173)
`ethyl ]-rapamycin
`The Novel Compounds for immunosuppressive use are
`preferably the 40-0-substituted rapamycins where X and Y
`are both 0, R2 isH, R4 is methyl. and R 1 is other than H;
`most preferably where R 1 is selected from hydroxyalkyl,
`hydroxyalkoxyalkyl, acylarninoalkyl. and arninoalkyl; espe-
`60 dally 40-0-(2-hydroxy)ethyl-rapamycin, 40-0-(3-hydroxy)
`propyl-rapamycin, 40-0-[2-(2-hydroxy)ethoxy]ethyl(cid:173)
`rapamycin, and 40-0-(2-acetarninoethyl)-rapamycin).
`Preferably 0-substitution at C40 or 0,0-disubstitution at
`C28 and C40 is performed according to the following
`65 general process: Rapamycin (or dihydro or
`deoxorapamycin) is reacted with an organic radical attached
`to a leaving group (e.g .. RX where R is the organic radical,
`
`41
`
`36
`
`wherein
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 002
`
`

`
`5,665,772
`
`10
`
`3
`e.g., an alkyl, allyl, or benzyl moiety, which is desired as the
`0-substituent, and X is the leaving group, e.g., CC13C
`(NH)O or CF3S03) under suitable reaction conditions, pref(cid:173)
`erably acidic or neutral conditions, e.g., in the presence of an
`acid like trifiuoromethanesulfonic acid, camphorsulfonic 5
`acid, p-toluenesulfonic acid or their respective pyridinium or
`substituted pyridinium salts when X is CC13(NH)O or in the
`presence of a base like pyridine, a substituted pyridine,
`diisopropylethylamine or pentamethylpiperidine when X is
`CF3S03• 0-substituents at C28 only are accomplished in the
`same manner, but with prior protection at C40. Further
`modifications are possible. For example, where the substitu(cid:173)
`ent is allyl, the isolated, monosubstituted double bond of the
`allyl moiety is highly amenable to further modification.
`The 9-deoxorapamycin compounds are preferably pro(cid:173)
`duced by reducing a rapamycin using hydrogen sulfide, by
`reacting rapamycin with diphenyldiselenide and tribu(cid:173)
`tylphosphine or by other suitable reduction reaction.
`The 26-dihydro-rapamycins are preferably produced by
`reducing rapamycins or 9-deoxorapamycins from keto to
`hydroxy at C26 by a mild reduction reaction, such as a
`borohydride reduction reaction.
`The Novel Compounds are particularly useful for the
`following conditions:
`a) Treatment and prevention of organ or tissue transplant
`rejection, e.g. for the treatment of recipients of e.g.
`heart, lung, combined heart-lung, liver, kidney,
`pancreatic, skin or corneal transplants. They are also
`indicated for the prevention of graft-versus-host
`disease, such as following bone marrow transplanta(cid:173)
`tion.
`b) Treatment and prevention of autoimmune disease and
`of inflammatory conditions, in particular inflammatory
`conditions with an etiology including an autoimmune
`component such as arthritis (for example rheumatoid
`arthritis, arthritis chronica progrediente and arthritis
`deformans) and rheumatic diseases. Specific autoim(cid:173)
`mune diseases for which the compounds of the inven(cid:173)
`tion may be employed include, autoimmune hemato(cid:173)
`logical disorders (including e.g. hemolytic anaemia,
`aplastic anaemia, pure red cell anaemia and idiopathic
`thrombocytopenia), systemic lupus erythematosus,
`polychondritis, sclerodoma, Wegener granulamatosis,
`dermatomyositis, chronic active hepatitis, myasthenia
`gravis, psoriasis, Steven-Johnson syndrome, idiopathic
`sprue, autoimmune inflammatory bowel disease
`(including e.g. ulcerative colitis and Crohn's disease)
`endocrine ophthalmopathy, Graves disease,
`sarcoidosis, multiple sclerosis, primary billiary
`cirrhosis, juvenile diabetes (diabetes mellitus type I),
`uveitis (anterior and posterior), keratoconjunctivitis
`sicca and vernal keratoconjunctivitis, interstitial lung
`fibrosis, psoriatic arthritis, glomerulonephritis (with
`and without nephrotic syndrome, e.g. including idio(cid:173)
`pathic nephrotic syndrome or minimal change
`nephropathy) and juvenile dermatomyositis.
`c) Treatment and prevention of asthma.
`d) Treatment of multi-drug resistance (MDR). The Novel
`Compounds suppress P-glycoproteins (Pgp ), which are
`the membrane transport molecules associated with
`MDR. MDR is particularly problematic in cancer
`patients and AIDS patients who will not respond to
`conventional chemotherapy because the medication is
`pumped out of the cells by Pgp. The Novel Compounds
`are therefore useful for enhancing the efficacy of other
`chemotherapeutic agents in the treatment and control of
`multidrug resistant conditions such as multidrug resis(cid:173)
`tant cancer or multidrug resistant AIDS.
`
`4
`e) Treatment of proliferative disorders, e.g. tumors, hyper(cid:173)
`proliferative skin disorder and the like.
`f) Treatment of fungal infections.
`g) Treatment and prevention of inflammation, especially
`in potentiating the action of steroids.
`h) Treatment and prevention of infection, especially infec(cid:173)
`tion by pathogens having Mip or Mip-like factors.
`i) Treatment of overdoses of FK-506, rapamycin, immu(cid:173)
`nosuppressive Novel Compounds, and other macrophi(cid:173)
`lin binding immunosuppressants.
`The invention thus provides the Novel Compounds
`described herein, for use as novel intermediates or as
`pharmaceuticals, methods of treating or preventing the
`above-described disorders by administering an effective
`15 amount of Novel Compound to a patient in need thereof, use
`of a Novel Compound in the manufacture of a medicament
`for treatment or prevention of the above-described disorders,
`and pharmaceutical compositions comprising a Novel Com(cid:173)
`pound in combination or association with a pharmaceuti-
`20 cally acceptable diluent or carrier.
`Most of the Novel Compounds described herein are
`highly immunosuppressive, especially those Novel Com(cid:173)
`pounds which are 0-substituted at C40, and these Novel
`Compounds are particularly useful in indications a and b, but
`25 not in indication i. Those of the Novel Compounds which are
`less immunosuppressive, especially those which are
`0-substituted at C28 only, are particularly useful in indica(cid:173)
`tions h and i, but are less preferred in indications a or b.
`The Novel Compounds are utilized by administration of a
`30 pharmaceutically effective dose in pharmaceutically accept(cid:173)
`able form to a subject in need of treatment. Appropriate
`dosages of the Novel Compounds will of course vary, e.g.
`depending on the condition to be treated (for example the
`disease type or the nature of resistance), the effect desired
`35 and the mode of administration.
`In general however satisfactory results are obtained on
`administration orally at dosages on the order of from 0.05 to
`5 or up to 10 mg!kg/day, e.g. on the order of from 0.1 to 2
`or up to 7.5 mg!kg/day administered once or, in divided
`40 doses 2 to 4x per day, or on administration parenterally, e.g.
`intravenously, for example by i.v. drip or infusion, at dos(cid:173)
`ages on the order of from 0.01 to 2.5 up to 5 mg!kg/day, e.g.
`on the order of from 0.05 or 0.1 up to 1.0 mg!kg/day.
`Suitable daily dosages for patients are thus on the order of
`45 500 mg p.o., e.g. on the order of from 5 to 100 mg p.o., or
`on the order of from 0.5 to 125 up to 250 mg i.v., e.g. on the
`order of from 2.5 to 50 mg i.v.
`Alternatively and even preferably, dosaging is arranged in
`patient specific manner to provide pre-determined trough
`50 blood levels, e.g. as determined by RIA technique. Thus
`patient dosaging may be adjusted so as to achieve regular
`on-going trough blood levels as measured by RIA on the
`order of from 50 or 150 up to 500 or 1000 ng/rnl, i.e.
`analogously to methods of dosaging currently employed for
`55 Ciclosporin immunosuppressive therapy.
`The Novel Compounds may be administered as the sole
`active ingredient or together with other drugs. For example,
`in immunosuppressive applications such as prevention and
`treatment of graft vs. host disease, transplant rejection, or
`60 autoimmune disease, the Novel Compounds may be used in
`combination with Ciclosporin, FK-506, or their immuno(cid:173)
`suppressive derivatives; corticosteroids; azathioprene;
`immunosuppressive monoclonal antibodies, e.g., mono(cid:173)
`clonal antibodies to CD3, CD4, CD25, CD28, or CD45; and
`65 7 or other immunomodulatory compounds. For anti(cid:173)
`inflammatory applications, the Novel Compounds can be
`used together with anti-inflammatory agents, e.g., corticos-
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 003
`
`

`
`5,665,772
`
`5
`teroids. For anti-infective applications, the Novel Com(cid:173)
`pounds can be used in combination with other anti-infective
`agents, e.g., anti-viral drugs or antibiotics.
`The Novel Compounds are administered by any conven(cid:173)
`tional route, in particular enterally, e.g. orally, for example 5
`in the form of solutions for drinking, tablets or capsules or
`parenterally, for example in the form of injectable solutions
`or suspensions. Suitable unit dosage forms for oral admin(cid:173)
`istration comprise, e.g. from 1 to 50 mg of a compound of
`the invention, usually 1 to 10 mg. Pharmaceutical compo- 10
`sitions comprising the novel compounds may be prepared
`analogously to pharmaceutical compositions comprising
`rapamycin, e.g., as described in EPA 0 041 795, which
`would be evident to one skilled in the art.
`The pharmacological activity of the Novel Compounds 15
`are demonstrated in, e.g., the following tests:
`1. Mixed lymphocyte reaction (MLR)
`The Mixed Lymphocyte Reaction was originally devel(cid:173)
`oped in connection with allografts, to assess the tissue
`compatibility between potential organ donors and recipients, 20
`and is one of the best established models of immune reaction
`in vitro. A murine model MLR, e.g., as described by T. Meo
`in "Immunological Methods", L. Lefkovits and B. Peris,
`Eds., Academic Press, N.Y. pp. 227-239 (1979), is used to
`demonstrate the immunosuppressive effect of the Novel 25
`Compounds. Spleen cells (0.5x106
`) from Balb/c mice
`(female, 8-10 weeks) are co-incubated for 5 days with
`0.5x106 irradiated (2000 rads) or mitomycin C treated
`spleen cells from CBA mice (female, 8-10 weeks). The
`irradiated allogeneic cells induce a proliferative response in 30
`the Balb/c spleen cells which can be measured by labeled
`precursor incorporation into the DNA. Since the stimulator
`cells are irradiated (or mitomycin C treated) they do not
`respond to the Balb/c cells with proliferation but do retain
`their antigenicity. The antiproliferative effect of the Novel 35
`Compounds on the Balb/c cells is measured at various
`dilutions and the concentration resulting in 50% inhibition
`of cell proliferation (IC50) is calculated. The inhibitory
`capacity of the test sample may be compared to rapamycin
`and expressed as a relative IC50 (i.e. IC50 test sample/IC50 40
`rapamycin).
`2. ll..--6 mediated proliferation
`The capacity of the Novel Compounds to interfere with
`growth factor associated signalling pathways is assessed
`using an interleukin-6 (ll..--6)-dependent mouse hybridoma 45
`cell line. The assay is performed in 96-well microtiter plates.
`5000 cells/well are cultivated in serum-free medium (as
`described by M. H. Schreier and R. Tees in Immunological
`Methods, L Lefkovits and B. Pernis, eds., Academic Press
`1981, Vol. n, pp. 263-275), supplemented with 1 ng recom- so
`binant IL-6/ml. Following a 66 hour incubation in the
`absence or presence of a test sample, cells are pulsed with
`1 !!Ci (3-H)-thymidinelwell for another 6 hours, harvested
`and counted by liquid scintillation. (3-H)-thymidine incor(cid:173)
`poration into DNA correlates with the increase in cell 55
`number and is thus a measure of cell proliferation. A dilution
`series of the test sample allows the calculation of the
`concentration resulting in 50% inhibition of cell prolifera(cid:173)
`tion (IC50). The inhibitory capacity of the test sample may
`be compared to rapamycin and expressed as a relative IC50 60
`(i.e. IC50 test sample/IC50 rapamycin).
`3. Macrophilin binding assay
`Rapamycin and
`the structurally related
`immunosuppressant, FK-506, are both known to bind in
`vivo to macrophilin-12 (also known as FK-506 binding 65
`protein or FKBP-12), and this binding is thought to be
`related to the immunosuppressive activity of these com-
`
`6
`pounds. The Novel Compounds also bind strongly to
`macrophilin-12, as is demonstrated in a competitive binding
`assay.
`In this assay, FK-506 coupled to BSA is used to coat
`microtiter wells. Biotinylated recombinant human
`macrophilin-12 (biot-MAP) is allowed to bind in the pres(cid:173)
`ence or absence of a test sample to the immobilized FK-506.
`After washing (to remove non-specifically bound
`macrophilin), bound biot-MAP is assessed by incubation
`with a streptavidin-alkaline phosphatase conjugate, fol(cid:173)
`lowed by washing and subsequent addition of p-nitrophenyl
`phosphate as a substrate. The read-out is the OD at 405 run.
`Binding of a test sample to biot-MAP results in a decrease
`in the amount ofbiot-MAPbound to the FK-506 and thus in
`a decrease in the OD405. A dilution series of the test sample
`allows determination of the concentration resulting in 50%
`inhibition of the biot-MAP binding to the immobilized
`FK-506 (IC50). The inhibitory capacity of a test sample is
`compared to the IC50 of free FK-506 as a standard and
`expressed as a relative IC50 (i.e., IC50-test sample!IC50-free
`FK-506).
`4. Localized Graft-Versus-Host (GvH) Reaction
`In vivo efficacy of the Novel Compounds is proved in a
`suitable animal model, as described, e.g., in Ford et al,
`TRANSPLANTATION 10 (1970) 258. Spleen cells (1x107
`)
`from 6 week old female Wistar/Furth (WF) rats are injected
`subcutaneously on day 0 into the left hind-paw of female
`(F344xWF)F 1 rats weighing about 100 g. Animals are
`treated for 4 consecutive days and the popliteal lymph nodes
`are removed and weighed on day 7. The difference in weight
`between the two lymph nodes is taken as the parameter for
`evaluating the reaction.
`5. Kidney Allograft Reaction in Rat
`One kidney from a female fisher 344 rat is transplanted
`onto the renal vessel of a unilaterally (left side) nephrecto(cid:173)
`mized WF recipient rat using an end-to-end anastomosis.
`Ureteric anastomosis is also end-to-end. Treatment com(cid:173)
`mences on the day of transplantation and is continued for 14
`days. A contralateral nephrectomy is done seven days after
`transplantation, leaving the recipient relying on the perfor(cid:173)
`mance of the donor kidney. Survival of the graft recipient is
`taken as the parameter for a functional graft.
`6. Experimentally Induced Allergic Encephalomyelitis
`(EAE) in Rats
`Efficacy of the Novel Compounds in EAE is measured,
`e.g., by the procedure described in Levine & Wenk, AMER
`J PATH 47 (1965) 61; McFarlin et al, J IMMUNOL 113
`(1974) 712; Borel, TRANSPLANT. & CLIN. IMMUNOL
`13 (1981) 3. EAE is a widely accepted model for multiple
`sclerosis. Male Wistar rats are injected in the hind paws with
`a mixture of bovine spinal cord and complete Freund's
`adjuvant. Symptoms of the disease (paralysis of the tail and
`both hind legs) usually develop within 16 days. The number
`of diseased animals as well as the time of onset of the disease
`are recorded.
`7. Freund's Adjuvant Arthritis
`Efficacy against experimentally induced arthritis is shown
`using the procedure described, e.g., in Winter & Nuss,
`ARI'HRIITS & RHEUMATISM 9 (1966) 394; Billingham
`& Davies, HANDBOOK OF EXPERIMENTALPHARMA(cid:173)
`COL (Vane & Ferreira Eds, Springer-Verlag, Berlin) 50/Il
`(1979) 108-144. OFA and Wistar rats (male or female, 150
`g body weight) are injected i.e. at the base of the tail or in
`the hind paw with 0.1 ml of mineral oil containing 0.6 mg
`of lyophilized heat-killed Mycobacterium smegrnatis. In the
`developing arthritis model, treatment is started immediately
`after the injection of the adjuvant (days 1-18); in the
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 004
`
`

`
`5,665,772
`
`7
`established arthritis model treatment is started on day 14,
`when the secondary inflammation is well developed (days
`14-20). At the end of the experiment, the swelling of the
`joints is measured by means of a micro-caliper. ED 50 is the
`oral dose in mg!kg which reduces the swelling (primary or
`secondary) to half of that of the controls.
`8. Antitumor and MDR activity
`The antitumor activity of the Novel Compounds and their
`ability to enhance the performance of antitumor agents by
`alleviating multidrug resistance is demonstrated, e.g., by
`administration of an anticancer agent, e.g., colchicine or
`etoposide, to multidrug resistant cells and drug sensitive
`cells in vitro or to animals having multidrug resistant or drug
`sensitive tumors or infections, with and without
`co-administration of the Novel Compounds to be tested, and
`by administration of the Novel Compound alone.
`Such in vitro testing is performed employing any appro(cid:173)
`priate drug resistant cell line and control (parental) cell line,
`generated, e.g. as described by ling et al., J. Cell. Physiol.
`83, 103-116 (1974) and Bech-Hansen et al. J. Cell. Physiol.
`88, 23-32 (1976). Particular clones chosen are the multi(cid:173)
`drug resistant (e.g. colchicine resistant) line CHR (subclone
`C5S3.2) and the parental, sensitive line AUX B1 (subclone
`AB1 Sll).
`In vivo anti-tumor and anti-MDR activity is shown, e.g.,
`in mice injected with multidrug resistant and drug sensitive
`cancer cells. Ehrlich ascites carcinoma (EA) sub-lines resis(cid:173)
`tant to drug substance DR, VC, AM, Ef, TE or CC are
`developed by sequential transfer of EA cells to subsequent
`generations of BALB/c host mice in accordance with the
`methods described by Slater et al., J. Clin. Invest, 70, 1131
`(1982).
`Equivalent results may be obtained employing the Novel
`Compounds test models of comparable design, e.g. in vitro,
`or employing test auimals infected with drug-resistant and
`drug sensitive viral strains, antibiotic (e.g. penicillin) resis(cid:173)
`tant and sensitive bacterial strains, anti-mycotic resistant and
`sensitive fungal strains as well as drug resistant protozoal
`strains, e.g. Plasmodial strains, for example naturally occur(cid:173)
`ring sub-strains of Plasmodium falciparum exhibiting
`acquired chemotherapeutic, anti-malarial drug resistance.
`9. FKBP binding
`Certain of the Novel Compounds are not
`immunosuppressive, particularly those which are
`0-substituted at C28 only, such as 28-0-methyl-rapamycin.
`This can be shown in standard in vitro assays in comparison
`to FK506 and rapamycin. FK506, for example, is known to
`be a potent inhibitor of IL-2 transcription, as can be shown
`in an IL-2 reporter gene assay. Rapamycin, although not
`active in the IL-2 reporter gene assay, strongly inhibits IL-6
`dependent T-cell proliferation. Both compounds are very
`potent inhibitors of the mixed lymphocyte reaction. Nonim(cid:173)
`munosuppressivity can also be shown in the in vivo models
`1-7 above. Even those Novel Compounds which are not
`immunosuppressive, however, bind to macrophilin, which 55
`confers certain utilities in which nonimmunosuppressivity is
`an advantage.
`Those of the Novel Compounds which bind strongly to
`macrophilin and are not themselves immunosuppressive can
`be used in the treatment of overdoses of macrophilin- 60
`binding immunosuppressants, such as FK506, rapamycin,
`and the immunosuppressive Novel Compounds.
`10. Steroid potentiation
`The macrophilin binding activity of the Novel Com(cid:173)
`pounds also makes them useful in enhancing or potentiating 65
`the action of corticosteroids. Combined treatment with the
`compounds of the invention and a corticosteroid, such as
`
`8
`dexamethasone, results in greatly enhanced steroidal activ(cid:173)
`ity. This can be shown, e.g., in the murine mammary tumor
`virus-chloramphenicol acetyltransferase (MMTV-CXI')
`reporter gene assay, e.g., as described inNing, et al., J. Bioi.
`5 Chern. (1993) 268: 6073. This synergistic effect allows
`reduced doses of corticosteroids, thereby reducing the risk of
`side effects in some cases.
`11. Mip and Mip-like factor inhibition
`Additionally, the Novel Compounds bind to and block a
`10 variety of Mip (macrophage infectivity potentiator) and
`Mip-like factors, which are structurally similar to macro(cid:173)
`philin. Mip and Mip-like factors are virulence factors pro(cid:173)
`duced by a wide variety of pathogens, including those of the
`genera Chlamidia, e.g., Chlamidia trachomatis; Neisseria,
`15 e.g., Neisseria meningitidis; and Legionella, e.g., Legionella
`pneumophilia; and also by the obligately parasitic members
`of the order Rickettsiales. These factors play a critical role
`in the establishment of intracellular infection. The efficacy
`of the Novel Compounds in reducing the infectivity of
`20 pathogens which produce Mip or Mip-like factors can be
`shown by comparing infectivity of the pathogens in cells
`culture in the presence and absence of the macrolides, e.g.,
`using the methods described in Lundemose, et al., Mol.
`Microbial. (1993) 7:777. The nonimmunosuppressive com-
`25 pounds of the invention are preferred for use in this indica(cid:173)
`tion for the reason that they are not immunosuppressive, thus
`they do not compromise the body's natural immune defenses
`against the pathogens.
`The Novel Compounds are also useful in assays to detect
`30 the presence or amount of macrophilin-binding compounds,
`e.g., in competitive assays for diagnostic or screening pur(cid:173)
`poses. Thus, in another embodiment, the invention provides
`for use of the Novel Compounds as a screening tool to
`determine the presence of macrophilin-binding compounds
`35 in a test solution, e.g., blood, blood serum, or test broth to
`be screened. Preferably, a Novel Compound is immobilized
`in microtiter wells and then allowed to bind in the presence
`and absence of a test solution to labelled macrophilin-12
`(FKBP-12). Alternatively, the FKBP-12 immobilized in
`40 microtiter wells and allowed to bind in the presence and
`absence of a test solution to a Novel Compound which has
`been labelled, e.g., :fiuoro-, enzymatically- or radio-labelled,
`e.g., a Novel Compound which has been 0-substituted at
`C40 and/or C28 with a labelling group. The plates are
`45 washed and the amount of bound labelled compound is
`measured. The amount of macrophilin-binding substance in
`the test solution is roughly inversely proportional to the
`amount of bound labelled compound. For quantitative
`analysis, a standard binding curve is made using known
`50 concentrations of macrophilin bind compound. ·
`
`EXAMPLES:
`In the following examples, characteristic spectroscopic
`data is given to facilitate identification. Peaks which do not
`differ significantly from rapamycin are not included. Bio(cid:173)
`logical data is expressed as a relative IC50, compared to
`rapamycin in the case of the mixed lymphocyte reaction
`(MLR) and IL-6 dependent proliferation (IL-6 dep. prol.)
`assays, and to FK-506 in the macrophilin binding assay
`(MBA). A higher IC50 correlates with lower binding affinity.
`Example 1: 40-0-Benzyl-rapamycin
`To a stirred solution of 183 mg (0.200 mmol) of rapamy(cid:173)
`cin in 2.1 mL of 2:1 cyclo-hexane-methylene chloride is
`added 75 J.1L (0.402 mmol) of benzyl-trichloroacetimidate,
`followed by 2.6 J.1L (29 J.IIllOl15 mol %) of tri:fiuoromethane(cid:173)
`sulfonic acid whereupon the mixture turned immediately
`yellow. Mter 3 h the mixture is diluted with ethyl acetate and
`
`Par Pharm., Inc.
`Exhibit 1001
`Page 005
`
`

`
`5,665,772
`
`9
`quenched with 10% aqueous sodium bicarbonate. The layers
`are separated and the aqueous layer is extracted twice with
`ethyl acetate. The combined organic solution is washed with
`10% aqueous sodium bicarbonate, dried over anhydrous
`sodium sulfate, filtered and concentrated under reduced 5
`pressure. The residue is purified by column chromatography
`on silica gel (50:50 hexane-ethyl acetate) to afford 40-0-
`benzyl-rapamycin as a white amorphous solid: 1H NMR
`(CDC13) 80.73 (lH, dd), 1.65 (3H, s), 1.73 (3H, s), 3.12 (4H,
`sand m), 3.33 (3H, s), 3.49 (3H, s), 4.15 (1H, bd), 4.65 (lH, 10
`d), 4.71 (1H, d), 7.22-7.38 (5H, m); MS (FAB) rn!z 1026
`([M+Na]+), 972 ([M-OCH3)]+), 954 ([M-(OCH3+H20)]+).
`
`MBA (rei. IC50)
`IL-6 dep. pro!. (rei. IC50)
`MLR (rei. IC50)
`
`1.8
`10
`110
`
`10
`4-yl)benzyl trichloroacetimidate, followed by 0.14 mL (0.64
`mmol) of 2,6-di-t-butylpyridine 56 J1L (0.64 mmol) of
`trifiuoromethanesulfonic acid. To this mixture is ·added a
`solution of 587 mg (0.64 mmol) of rapamycin in 2 mL of
`methylene chloride. The reaction is stirred overnight at room
`temperature and quenched with aqueous sodium bicarbon(cid:173)
`ate. The layers are separated and the aqueous layer is
`extracted twice with ethyl acetate. The combined organic
`solution is washed with saturated brine, dried over anhy(cid:173)
`drous sodium sulfate, filtered and concentrated. The residue
`is purified by column chromatography on silica gel (50:50
`hexane-ethyl acetate) to give 40-0-[4'-(2,2-Dimethyl-1,3-
`dioxolan-4-yl)]benzyl-rapamycin as a white, amorphous
`15 solid: 1H NMR (CDC13) 00.73 (lH, dd), 1.48 (3H, s), 1.55
`(3H, s), 1.65 (3H, s), 1.74 (3H, s), 3.67 (3H, m), 4.28 (lH,
`dd), 4.62 (lH, d), 4.69 (1H, d), 5.06 (lH, dd), 7.33 (4H, m),
`MS (FAB) rnlz 1126 ([M+Na]+), 1072 ([M-OCH3]+), 1054
`([M-OCH3+H20W), 1014 ([M-(OCH3+CH3COCH3)]+),
`Example 2: 40-0-(4'-Hydroxymethyl)benzyl-rapamycin
`a) 40-0-[4'-(t-Butyldimethylsilyl)oxymethyl]benzyl- 20 996 ([M-(OCH3+H20+CH3COCH3)]~, 978 ([M-(OCH3+
`2H20+CH3COCH3W).
`rapamycin
`To a stirred. cooled (-78° C.) solution of 345 J1L (2.0
`b) 40-0-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin
`To a solution of 90.7 mg (0.08 mmol) of 40-0-[ 4'-(2,2-
`mmol) of triflic anhydride in 5 mL of methylene chloride is
`added a solution of 504 mg (2.0 mmol) of 4-(t-
`butyld.imethylsilyl)oxymethyl-benzyl alcohol and 820 mg
`Dimethyl-1,3-dioxolan-4-yl)]benzyl-rapamycin in 4 mL of
`(4.0 mmol) of 2,6-di-t-butyl-4-methyl-pyridine in 5 mL of
`methanol is added 1 mL of 1N aqueous HCl. After 2 h the
`methylene chloride. The resulting mixture is warmed to
`mixture is quenched with aqueous sodium bicarbonate and
`-zoo c. and stirring is continued at this temperature for O.S
`extracted twice with ethyl acetate. The organic solution is
`h. The mixture is then cooled back to -78° C. and a solution
`washed with brine, dried over anhydrous sodium sulfate and
`of 914 mg (1.0 mmol) of rapamycin in 5 mL of methylene 30 concentrated. The residue is purified by column chromatog-
`chloride is added. This mixture is allowed to warm to room
`raphy on silica gel (ethyl acetate) and the title compound is
`obtained as a white foam: 1H NMR (CDC13) 00.73 (lH, dd),
`temperature overnight and is then quenched with 10%
`aqueous sodium bicarbonate. The layers are separated and
`1.65 (3H, s), 1.74 (3H, s), 3.70 (4H, m), 4.63 (1H, d), 4.69
`the aqueous layer is extracted with ethyl acetate. The com-
`(1H, d), 4.80 (1H, dd), 7.33 (4H, m); MS (FAB) rnlz 1086
`bined organic solution is washed with saturated brine, dried 35 ([M+Nat), 1032 ([M-OCH3t), 1014 ([M-OCH3+H20)]~,
`over sodium sulfate, filtered under reduced pressure and
`996 ([M-(OCH3+2H20)t).
`concentrated. The residue is purified by column chromatog-
`raphy on silica gel (50:50 hexane-ethyl acetate) to afford
`40-0- [ 4' -( t-buty ldimethy lsilyl)oxymethy l]benzyl(cid:173)
`rapamycin a white foam: MS (FAB) rnlz 1170 ([M+Na]+), 40
`1098 ([M-(OCH3+H20W).
`b) 40-0-( 4' -Hydroxymethyl)benzyl-rapamycin
`To a stirred, cooled

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket